Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3256)	9/30/2002 11:46:43 PM
From: mopgcw	Read Replies (1) \| Respond to of 4974

I have been thinking about it... Let's even assume the IPO was over-priced. Cut it in half, and you are still above current prices. The fall as a result of the disclosure event is BS. at the end of the day, a couple things in the pipeline, cash in the bank...

To: scaram(o)uche who wrote (3256)	9/30/2002 11:57:04 PM
From: scaram(o)uche	Respond to of 4974

IDEC Pharmaceuticals and Nippon Shinyaku Sign License Agreement to Develop Novel, Anti-Cancer Drug Monday September 30, 10:00 pm ET SAN DIEGO and KYOTO, Japan--(BUSINESS WIRE)--Sept. 30, 2002--IDEC Pharmaceuticals Corporation (Nasdaq: IDPH - News) and Nippon Shinyaku Co., Ltd. announced signing a licensing agreement for a novel, small-molecule, anti-cancer therapeutic agent, known as HMN-214. Nippon Shinyaku has granted IDEC a worldwide license for the therapeutic agent, except in Japan and Asia. HMN-214 is an orally administered stilbene pro-drug which has shown anti-tumor activity in a broad spectrum of human tumor cell lines in pre-clinical studies. (snip) Cambridge Antibody Technology Partners With Chugai to Develop Novel Human Monoclonal Antibodies Commitment to the custom development of human antibody-based therapeutics Monday September 30, 3:08 am ET MELBOURN, England, Sept. 30 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology (Nasdaq: CATG - News; LSE: CAT - News) today announces an agreement with Chugai Pharmaceutical Co., Ltd. (TSE 4519), of Japan to license CAT's proprietary antibody phage display libraries for the discovery, development and commercialization of human monoclonal antibodies. Under the terms of the agreement, CAT will receive license fees from Chugai to utilize the antibody libraries for reagent generation and target validation in support of drug discovery programs at Chugai. In addition, Chugai will receive exclusive therapeutic antibody product options and CAT will receive fees, clinical milestones and royalty payments on product sales. (snip)